AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$NRIX

Ring Christine sold $149K of NRIX

Ring Christine (Chief Legal Officer) sold 5,787 shares of Nurix Therapeutics, Inc. (NRIX) at an average of $25.76 ($25.69–$26.64, $0.15M total) across 2 trades on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ring Christine
Published Sep 2, 2026, 11:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 12:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NRIX
Neutral
high confidence
Mentioned
$NRIX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRIXNeutralLow
01

Why it matters

The transaction is small and pre‑arranged, so market reaction is expected to be muted.

02

Market read

Limited relevance; typical insider sale with minimal impact on NRIX stock.

03

What to watch

Potential future insider purchases or broader ownership changes not disclosed.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-02

Background

Form 4 filings disclose insider transactions; this filing reports a routine sale by a senior officer.

Company-level read

Ticker impact

$NRIXNeutralHigh confidence
Context

Chief Legal Officer sold $149K of NRIX shares via a 10b5-1 plan on 2026-09-02.

Expected impact

No material move expected.

Evidence & confidence

Sale size is small relative to market cap and follows a pre‑arranged plan.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider sale could be interpreted as lack of confidence, but size is trivial.

Key entities

  • Officer
    Ring Christine

    Chief Legal Officer of Nurix Therapeutics, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NRIX insider trading history →

Related articles

Med

Nurix Therapeutics stock is up, what you need to know

Nurix Therapeutics (NRIX) shares rose 3.4% after appointing Dr. Arati V. Rao as chief medical officer. Dr. Rao will oversee clinical development, including the BTK degrader bexobrutideg partnered with Roche. The stock closed at $16.33, up 2.8% from the previous close. Nurix has faced volatility, including a 39.8% drop last week due to Sanofi ending a Phase 1 study. The company has $1.1B in cash, funding operations into 2029.

tradingview.com
$NRIXHighAI 8/10

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

Nurix Therapeutics (NRIX) shares fell 38% after Sanofi (SNY) terminated development of a key Phase I immunology candidate, SAR448272 (NX-3911), under their collaboration. Despite this, the rest of the collaboration remains intact, and Nurix maintains a strong cash position. Analysts note Nurix's potential in the oral protein degrader space, particularly its partnership with Roche (RO) for bexobrutideg (NX-5948), which targets a $48B market opportunity across five diseases.

genengnews.com
$NRIXMedAI 8/10

Nurix to present bexobrutideg data at ASH meeting

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.

investing.com